Articles related to OPIOIDS

“Pharmacies exist to heal the sick, not to fuel addiction and line the pockets of drug traffickers.” – DEA Administrator Terrance Cole

The research suggests that patients with cancer who previously received preventative prescriptions even without pain may now be less likely to receive a prescription until they begin reporting pain.

Integrating suzetrigine and cebranopadol into multimodal treatment algorithms may reduce opioid doses, improve patient function and expand options for those at risk of opioid-related harms.

“The death of almost one million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,” said FDA Commissioner Marty Makary, M.D., M.P.H. “This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and post-market monitoring so that nothing like this ever happens again.”

With more potent forms of opioids on the street, overdoses from illicit drugs are at an all-time high and withdrawal from them is often more severe.

Suzetrigine, a newly approved NaV1.8 inhibitor, offers a promising non-opioid alternative for managing moderate-to-severe acute pain, backed by robust clinical trial data.